Company Overview and News

 
D-Street Buzz: IT, pharma stocks rise led by Wipro, Dr Reddy#39;s Labs; Network18 zooms 15%

2018-09-03 moneycontrol
The Indian market is trading on a handsome note this Monday morning with the Nifty50 up 32 points at 11,712 while the Sensex is trading higher by 124 points at 38,769.
EKC BAJAJ-AUTO TCHQY 532977 532755 CADILAHC 505200 532321 532684 500477 500493 EICHERMOT BHARATFORG ASHOKLEY EXIDEIND ECQRY 517354 HINDALCO HVLQY ALBERTDA AKLD CDLYY TECHM HNDNF EXQDY 524075 GAMMONIND HAVELLS 509550 GOODRICKE 500086 AKLS 500440 500166

 
Godfrey Phillips posts Q4 net profit at Rs43 crore

2018-05-29 livemint
New Delhi:Cigarette maker Godfrey Phillips India on Tuesday reported a standalone net profit at Rs43.11 crore for the fourth quarter ended March 2018.
GOODRICKE GODFRYPHLP 500163 500166

 
NCLT wants Assam Co. bidding norms revised

2018-04-28 livemint
Kolkata: A suitor for Assam Co. India Ltd—the country’s oldest surviving and perhaps most prized tea company (in terms of assets), now going through insolvency resolution—has successfully petitioned the National Company Law Tribunal (NCLT) to dilute eligibility conditions for bids.
GOODRICKE 508494 538564 JAMESWARREN WARRENTEA 500166

 
Andrew Yule sells early harvest tea from Mim estate, Darjeeling at record price

2018-04-13 livemint
Kolkata: State-owned Andrew Yule and Co. Ltd on Friday announced that it had sold early harvest, or first flush tea from its Mim estate in Darjeeling district at Rs15,750 per kg, a record price for the garden.
526173 GOODRICKE 500166 ANDREWYU

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...